61 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
or by developing innovative therapeutics; products under development by Ligand or its partners may not receive regulatory approval; the total addressable market
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
or partnered pipeline; Ligand may not achieve its guidance for 2023; Ligand may not be able to create future revenues and cash flows by developing innovative
425
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
21 Jun 22
Business combination disclosure
8:00am
to enable discovery of next - generation therapeutics. Value Proposition
9 Mission Our mission is to enable the rapid development of innovative
8-K
EX-99.1
mjd961t6o314wz452
21 Jun 22
Regulation FD Disclosure
6:19am
425
EX-99.3
wz4zlesjc ka0cpyudok
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.3
hsxygg
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.1
n7cm75d1
17 Feb 22
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
4:03pm
8-K
EX-99.1
h5nczi8ozom2adegnf
3 Feb 21
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
7:45am
8-K
EX-99.1
md4 6lluccl3id1
21 Dec 20
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
8:39am
8-K
EX-99.1
lrp8aszjlc5nfa17egw
6 May 20
Ligand Reports First Quarter 2020 Financial Results
4:03pm
8-K
EX-99.1
p8eu64
2 Apr 20
Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs
4:18pm
8-K
EX-99.1
weny0 rcq
6 Feb 20
Ligand Reports Fourth Quarter and Full Year 2019 Financial Results
4:05pm
8-K
EX-99.1
ncn1cd2hlj
5 Nov 19
Ligand Reports Third Quarter 2019 Financial Results
4:05pm
8-K
EX-99.1
n3k c848bsm
30 Jul 19
Ligand Reports Second Quarter 2019 Financial Results
8:13am
8-K
EX-99.1
42rso1ez7c504
2 May 19
Ligand Reports First Quarter 2019 Financial Results
4:09pm
8-K
EX-99.1
kxxmx6
12 Mar 19
Regulation FD Disclosure
10:02am